Selonsertib (Ser), a selective inhibitor of Apoptosis Signal-regulated kinase-1 (ASK1), has earned its reputation for its anti-inflammatory and anti-apoptotic properties in nonalcoholic steatohepatitis therapy (Loomba et al., 2018). This evidence concerns the gene MAP3K5 and metabolic dysfunction-associated steatohepatitis.